GLPwatch
[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Rev Med Suisse · 2016
Last updated 2026-05-28Two studies found that two diabetes drugs—empagliflozin and liraglutide—reduced major heart-related events by 14% and 13%, heart-related deaths by 38% and 22%, and overall deaths by 32% and 15% compared to a placebo in people with type 2 diabetes and high heart risk. Both drugs also slowed kidney disease progression and reduced kidney-related events.
AI summary of the abstract below.
| Journal | Rev Med Suisse, 2016 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with type 2 diabetes and high cardiovascular risk. Empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME, and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER, showed a significant reduction in major cardiovascular events (- 14 and - 13 %, respectively), cardiovascular mortality (- 38 and - 22 %, respectively) and all-cause mortality (- 32 and - 15 %, respectively). A lower progression of kidney disease and less renal events were also reported. The underlying protective mechanisms remain controverted as the discussion whether the benefits are specific to each medication or could be extended to other molecules of these two pharmacological classes.
Verbatim abstract via PubMed 28671791 ↗